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September 22, 2009:1190–4f our patients were affected by a chronic active myocarditis, a
ell-established clinico-pathologic entity characterized by ongoing
yocardial inflammation and necrosis with different degrees of
eplacement fibrosis in patients with chronic symptoms (in this
ase, ventricular arrhythmias). Although not detailed in this study,
e previously reported that patients with chronic active myocar-
itis mimicking ARVC present, at histomorphometric analysis,
alues of fibrosis comparable to patients with a histological
iagnosis of ARVC (4). Accordingly, as clearly documented in
able 2 of the present study (1), we failed to observe any difference
n terms of delayed enhancement between the 2 groups. Never-
heless, we think that fibrosis should not be considered the unique
istological substrate of low-voltage areas, grossly defined by
lectrophysiologists as “scar.” We learned from cardiac magnetic
esonance how delayed enhancement, initially considered synony-
ous with fibrosis, could indeed result from any cause of intersti-
ial expansion including edema, necrosis, inflammation, or amyloid
eposition. Similarly, inflammation might modulate electrical
roperties of myocardium inducing a low-voltage area before
eplacement fibrosis occurs. The adoption of the simplistic equa-
ion: low-voltage  fibrosis, may retard the comprehension of
rrhythmogenesis in myocardial disorders.
Our study demonstrates that current diagnostic criteria should be
evisited and suggests that further studies including both electroana-
omic mapping-guided endomyocardial biopsy and genetic analysis of
atients with familial and sporadic forms of ARVC will allow
larification of the complex link between desmosomal abnormalities,
nflammation, and fibrofatty replacement.
It is noteworthy that the angiographic picture of “pile
’assiettes” [pile of dishes] in a patient with myocarditis was
hosen to emphasize the possible overlap of angiographic findings
etween ARVC and myocarditis.
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2004;43:2305–13.ulmonary Hypertension in
eart Failure With Preserved
jection Fraction
ny Pathophysiological Role of
itral Regurgitation
read with interest the study by Lam et al. (1) as an important
ontribution to the pathophysiological and clinical impact of
ulmonary hypertension (PH) in hypertensive patients with
eart failure and preserved left ventricular ejection fraction
HFpEF). Recent guidelines on arterial PH recognize HFpEF
s a growing cause of left-sided PH (2), but a definitive
ppreciation of its true prevalence and prognostic relevance is
acking. The present study provides some new important
nformation on this subject.
It is noteworthy that HFpEF was associated, in a high rate of
ases (83%), with a typical hemodynamic pattern of pre-
apillary PH, and a strong correlation was found between
ulmonary artery systolic pressure and pulmonary capillary
edge pressure. Most important, pulmonary artery systolic
ressure, rather than other echocardiography-derived measures
f diastolic dysfunction, was the only significant multivariate
redictor of mortality, a finding that was confirmed even when
ombined comorbid diseases potentially contributing to PH
evelopment, such as chronic obstructive pulmonary disease,
ere taken into account.
In patients with systolic heart failure, a major determinant of
H development is mitral regurgitation (3,4). Whether mitral
egurgitation could be a putative factor in the pathogenesis of
H in HFpEF patients remains an open and intriguing ques-
ion. Accordingly, it would be of interest if the authors could
rovide some details on how many HFpEF patients exhibited
itral regurgitation, especially in comparison with control
ypertensive patients without HFpEF. Definitive appreciation
f the relative pathophysiological role of mitral insufficiency in
he PH development and severity may predictably represent a
tep forward in the progressive fascinating characterization of
FpEF patients.
Marco Guazzi, MD, PhD
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eply
e appreciate these insightful comments on our paper (1) and
ully agree that mitral regurgitation can importantly contribute to
he development of pulmonary hypertension in left-sided heart
ailure. As demonstrated in heart failure with reduced ejection
raction (2,3), hemodynamically significant mitral regurgitation
an cause left atrial volume and pressure overload with resultant
ncreases in pulmonary artery systolic pressure independent of left
entricular filling pressures. As noted in the Methods section (1),
n our sample of heart failure with preserved ejection fraction
HFpEF), patients with hemodynamically significant (greater than
oderate) mitral regurgitation were excluded in accordance with
merican College of Cardiology/American Heart Association
uidelines for the diagnosis of HFpEF (4). In our hypertensive
ontrol group from the general community, clinically significant
itral valve disease was exceedingly rare (n  2, 0.4%). Thus, we
onclude that mitral regurgitation at rest did not contribute to the
evelopment of pulmonary hypertension in our sample.
One could speculate that hemodynamic stress during periods of
ypertension or exercise could produce intermittent mitral regurgita-
ion and contribute to the development of pulmonary hypertension.
owever, we excluded patients with intrinsic valve disease (mitral
alve prolapse, and so on) who would be susceptible to stress-induced
orsening of mitral regurgitation. Further, in contrast to heart failure
ith reduced ejection fraction, the lack of ventricular dilation in
FpEF would make it unlikely for significant “functional” mitral
egurgitation to develop. We did not exclude patients with coronary
rtery disease, which could cause ischemic mitral regurgitation with
tress. Hence, while we agree that mitral regurgitation can contribute
o pulmonary hypertension in heart failure patients, it would seem
nlikely to be a major contributor in this cohort.
arolyn S. P. Lam, MBBS
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enal Protective
ffects and Prevention of
ontrast-Induced Nephropathy
y Atrial Natriuretic Peptide
an It Work?
e congratulate Morikawa et al. (1) on this important paper on
herapeutic prevention of contrast-induced nephropathy, and
hen (2) for his editorial comment putting this research into
erspective. The editorial comment already mentioned many
ositive aspects of the study.
Contrast-induced nephropathy frequently complicates primary
ercutaneous coronary intervention (3). In the present study,
orikawa et al. (1) chose an intermediate dose of atrial natriuretic
eptide (ANP) at 0.042 g/kg/min to prevent contrast-induced
ephropathy and found—corresponding with the physiological
ffect of “natriuretic” peptide—increased diuresis associated with a
tatistically significant but clinically perhaps not meaningful
hange of glomerular markers (serum creatinine, estimated glo-
erular filtration rate, cystatin C) at 1 month after the procedure
ompared with control, for example, a reduced loss of estimated
lomerular filtration rate 1 ml/min/1.73 m2. The relevance of
his finding is further questioned by the lack of an effect of ANP
n markers of tubular damage (urinary microglobulin and
-acetyl-D-glucosaminidase), although contrast-induced ne-
hropathy has been described involving tubular damage.
A previous randomized controlled trial using nesiritide pre-
ented during the Congress of the American Society of Nephrol-
gy 2008 (4) showed an absolute reduction in the incidence of
cute kidney injury after cardiac surgery similar to that of the
resent study (1), but although powered for it, the former study
ould not demonstrate a reduced need for dialysis and was
iscontinued after an interim analysis (4).
It would strengthen the message further to discuss why, in the
tudy by Morikawa et al. (1), N-acetylcysteine has not been used
or nephroprotection although N-acetylcysteine has been shown to
educe the incidence of contrast-induced nephropathy and the
ortality associated with it (5,6). N-acetylcysteine does not arti-
cially reduce serum creatinine concentration (7), which was a
revious concern (8), and its use is current clinical practice for
atients undergoing angiography who present with chronic kidney
isease at many European centers.
